Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biogen Idec, a manufacturer of biologics, has reported a net income of $246.58 million, or $0.84 per diluted share for the first quarter of 2009, compared to $165.81 million or $0.54 per diluted share for the first quarter of 2008.
Subscribe to our email newsletter
The company has reported a revenue of $1.04 billion for the first quarter of 2009, a 10% increase, compared to $942.19 million for the first quarter of 2008.
James Mullen, Biogen Idec’s president and CEO, said: “Revenue growth from all three of our marketed products and continued advancement of our robust pipeline during the quarter were in line with our expectations.
“The expansion of our global footprint in recent years is serving us well, particularly in the current environment. One-third of our sales currently come from outside the US, a clear illustration of our success in capturing the greatest amount of value for our products worldwide.”